Stem Cell Therapy Market by Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs), Therapeutic Application, End-User - Global Forecas

Stem Cell Therapy Market by Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs), Therapeutic Application, End-User - Global Forecast 2024-2030


The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.20 million in 2024, at a CAGR 12.88% to reach USD 1,027.29 million by 2030.

Global Stem Cell Therapy Market

Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.

Regional Insights

In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Stem Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Gilead Sciences, Inc., Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Allogeneic Stem Cell Therapy
Autologous Stem Cell Therapy
Cell Source
Adipose Tissue-Derived MSCs
Bone Marrow-Derived MSCs
Placental / Umbilical Cord-Derived MSCs
Therapeutic Application
Cardiovascular Diseases Surgeries
Inflammatory & Autoimmune Diseases
Musculoskeletal Disorders
Neurological Disorders
Orthopedics & Rheumatoid
Wounds & Injuries
End-User
Academic & Research Centers
Ambulatory Surgical Centers
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Stem Cell Therapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cell Therapy Market?
3. What are the technology trends and regulatory frameworks in the Stem Cell Therapy Market?
4. What is the market share of the leading vendors in the Stem Cell Therapy Market?
5. Which modes and strategic moves are suitable for entering the Stem Cell Therapy Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Stem Cell Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
5.1.1.2. Increasing government initiatives for stem cell therapy across the world
5.1.1.3. Expansion of stem cell therapy centers and clinics
5.1.2. Restraints
5.1.2.1. Difficulties associated with performing stem cell therapy
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in stem cell therapy
5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
5.1.4. Challenges
5.1.4.1. Ethical and safety issues of stem cell-based therapy
5.2. Market Segmentation Analysis
5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
5.3. Market Trend Analysis
5.3.1. Rigorous stem cell therapy based research initiatives, evolving regulatory frameworks, and an increasing demand for advanced therapies is fueling market in Americas
5.3.2. Advancements in stem cell therapies backed by government fundings and rising adoption due to medical tourism practices in the APAC countries
5.3.3. Strong network of academic institutions and biotech firms backed by government funding to accelerate stem cell research and commercialization in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Stem Cell Therapy Market, by Type
6.1. Introduction
6.2. Allogeneic Stem Cell Therapy
6.3. Autologous Stem Cell Therapy
7. Stem Cell Therapy Market, by Cell Source
7.1. Introduction
7.2. Adipose Tissue-Derived MSCs
7.3. Bone Marrow-Derived MSCs
7.4. Placental / Umbilical Cord-Derived MSCs
8. Stem Cell Therapy Market, by Therapeutic Application
8.1. Introduction
8.2. Cardiovascular Diseases Surgeries
8.3. Inflammatory & Autoimmune Diseases
8.4. Musculoskeletal Disorders
8.5. Neurological Disorders
8.6. Orthopedics & Rheumatoid
8.7. Wounds & Injuries
9. Stem Cell Therapy Market, by End-User
9.1. Introduction
9.2. Academic & Research Centers
9.3. Ambulatory Surgical Centers
9.4. Biotechnology & Pharmaceutical Companies
9.5. Hospitals & Clinics
10. Americas Stem Cell Therapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Stem Cell Therapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Stem Cell Therapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Selecta Biosciences Announces Merger with Cartesian Therapeutics
13.3.1.2. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
13.3.2.2. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
13.3.2.3. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
13.3.2.4. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
13.3.2.5. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
13.3.3. Investment & Funding
13.3.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
13.3.3.2. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
13.3.3.3. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
13.3.3.4. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
13.3.4. Award, Recognition, & Expansion
13.3.4.1. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
13.3.4.2. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
13.3.4.3. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
13.3.4.4. Novo Nordisk to Expand R&D Presence in Greater Boston Area
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. 4D Molecular Therapeutics, Inc.
14.1.2. Anterogen Co., Ltd.
14.1.3. Astellas Pharma Inc.
14.1.4. Athersys, Inc.
14.1.5. Aurion Biotechnologies
14.1.6. Beike Biotechnology Co., Ltd.
14.1.7. BrainStorm Cell Therapeutics Inc.
14.1.8. Bristol-Myers Squibb Company
14.1.9. CellProthera
14.1.10. Fate Therapeutics, Inc.
14.1.11. Gamida Cell Ltd.
14.1.12. Garuda Therapeutics
14.1.13. Gilead Sciences, Inc.
14.1.14. Holostem Terapie Avanzate S.r.l.
14.1.15. Jasper Therapeutics, Inc.
14.1.16. JCR Pharmaceuticals Co., Ltd.
14.1.17. Juvena Therapeutics Inc.
14.1.18. Kangstem Biotech., Ltd.
14.1.19. Lineage Cell Therapeutics, Inc.
14.1.20. Lonza Group AG
14.1.21. Mesoblast Ltd.
14.1.22. Novo Nordisk A/S
14.1.23. Plasticell
14.1.24. ReNeuron Group PLC
14.1.25. Sartorius CellGenix GmbH
14.1.26. SQZ Biotechnologies Company
14.1.27. Takara Bio Inc.
14.1.28. U.S. Stem Cell Inc
14.1.29. Umoja Biopharma
14.1.30. Vericel Corporation
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. STEM CELL THERAPY MARKET DYNAMICS
FIGURE 7. STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
FIGURE 10. STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
FIGURE 12. STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings